✨ Free AI Report
Codexis, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Codexis, Inc.
Company Research

Codexis, Inc.: Business Overview, Financials & Competitive Analysis

Codexis, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). High-growth potential in RNA therapeutics manufacturing offset by near-term profitability challenges and execution risks during business transformation. Net loss for Q3 2025 was $19.6 million, indicating significant near-term costs of transition. However, the ECO Synthesis™ platform is designed to revolutionize siRNA manufacturing, which is a rapidly growing area in therapeutics.

What is Codexis, Inc.'s industry? Codexis, Inc. (codexis.com) operates in Biopharmaceutical Manufacturing / Synthetic Biology. AskCyborg classifies Codexis, Inc. under Biopharmaceutical Manufacturing / Synthetic Biology in its company registry.

Codexis is a leading enzyme engineering company powering scalable, sustainable solutions for therapeutic development. With its proprietary CodeEvolver® platform and ECO Synthesis™ platform, the company creates manufac...

4/ 10Mixed

Cyborg Score thesis

High-growth potential in RNA therapeutics manufacturing offset by near-term profitability challenges and execution risks during...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Manufacturing / Synthetic Biology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Codexis, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Codexis, Inc.

AskCyborg analysts argue the bull and bear cases for Codexis, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Codexis, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Codexis, Inc. Overview

Pro stress-test →

Codexis is a leading enzyme engineering company powering scalable, sustainable solutions for therapeutic development. With its proprietary CodeEvolver® platform and ECO Synthesis™ platform, the company creates manufacturing solutions delivering enzymes that outperform legacy methods across RNAi therapeutics, diagnostics, and small molecule manufacturing.

Strategic Profile

Pro stress-test →

The company is navigating a complex transition moving toward full-service oligonucleotide manufacturing, backed by a crucial $37.8 million supply agreement with Merck. The company is actively shifting away from its legacy small molecule biocatalysis business to focus on the ligase and ECO Synthesis™ business lines, representing a high-risk, high-reward strategic repositioning.

Competitive Landscape

Pro stress-test →

Codexis differentiates through methodical approach, rigorous process development, and integration of advanced screening technologies; its work in optimizing yield, purity, and process quality makes it a noteworthy player in the biotechnology landscape. Enzyme-powered processes drive measurable impact with fewer impurities, faster timelines, and reduced waste and energy use.

Industry Context

Codexis, Inc. operates in Biopharmaceutical Manufacturing / Synthetic Biology.

Key facts

Founded: 2002 · Headquarters: Redwood City, California · Employees: Unknown · Revenue: $0.064-0.068B · Market cap: $0.085B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Codexis, Inc..

  • Appointment of Dr. Alison Moore as CEO effective November 7, 2025, signals leadership commitment to therapeutic focus
  • Actively shifting away from legacy small molecule biocatalysis business facing pricing pressure toward higher-margin ECO Synthesis platform
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Dr. Alison Moore appointed as CEO
  • Q3 2025$19.6 million net loss and 24% workforce reduction announced
  • +1 moreTrack every material event for Codexis, Inc. as it happens. Explore monitoring →
Get alerted when Codexis, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Synthetic Biology & Enzyme EngineeringEnzyme engineering and synthetic biology platforms→Oligonucleotide ManufacturingRNA and oligonucleotide synthesis and manufacturing→Biocatalysis SolutionsIndustrial enzyme and biocatalysis services→

Compare Codexis, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Codexis, Inc. operates in Biopharmaceutical Manufacturing / Synthetic Biology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Manufacturing / Synthetic Biology research →
NEW · MCP server

Ask your AI assistant about Codexis, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Codexis, Inc. and its top competitor on Cyborg Score”
“What did Codexis, Inc. do this quarter?”
“Is Codexis, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Codexis, Inc. do?+
Codexis is a leading enzyme engineering company powering scalable, sustainable solutions for therapeutic development. With its proprietary CodeEvolver® platform and ECO Synthesis™ platform, the company creates manufac...
What is Codexis, Inc.'s Cyborg Score?+
Codexis, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Codexis, Inc.'s main competitors?+
Named competitors include Synthetic Biology & Enzyme Engineering, Oligonucleotide Manufacturing, Biocatalysis Solutions. The full competitive landscape is in the AskCyborg report.
How can I get the full Codexis, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Codexis, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Codexis, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.